Loading clinical trials...
Loading clinical trials...
The Effects of Real-time Continuous Glucose Monitoring on Glycemia and Quality of Life in Patients With Type 1 Diabetes Mellitus and Impaired Hypoglycemia Awareness
The purpose of this study is to determine what the effects are of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired hypoglycemia awareness.
The investigators hypothesize that the use of RT-CGM, relative to a control intervention using masked CGM, will result in improvement of various measures of glycemia and indicators of quality of life, reduce the occurrence of hypoglycemia and hyperglycemia and restore hypoglycemia awareness in T1DM patients with IHA. We will test this hypothesis by addressing the following research questions: What is the effect of 16 weeks of RT-CGM use, versus 16 weeks of CGM use, in patients with T1DM and IHA on 1. (primary objective:) time spent in euglycemia 2. (secondary objectives:) * (diabetes-specific) markers of QoL, covering diabetes-related emotional distress (PAID-5), fear of hypoglycemia (HFS-2), self-efficacy (CIDS), health status (EQ5D) and emotional well-being (WHO-5) * other glycemia variables, including HbA1c and time spent in hypo- and - hyperglycemia ranges * the incidence and duration of hypoglycemic episodes * changes in hypoglycemia awareness score according to Gold et al., 3. (tertiary objectives:) * measures of glucose variability * the autonomic nervous system balance * the duration of wear of the RT-CGM device * patients' therapy adjustments during the interventions * hypoglycemia awareness scores according to Clarke et al. * satisfaction with use of CGM * the number of contact moments not planned according to the study schedule * absence of work of patient (and spouse) * the global estimated costs of use of health care
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
VU University Medical Center
Amsterdam, North Holland, Netherlands
Start Date
February 1, 2013
Primary Completion Date
April 1, 2016
Completion Date
April 1, 2016
Last Updated
July 26, 2017
52
ACTUAL participants
Real-time continuous glucose monitor
DEVICE
Lead Sponsor
Amsterdam UMC, location VUmc
Collaborators
NCT03970720
NCT07051005
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06390371